

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 February 2017 (02.02.2017)



(10) International Publication Number
WO 2017/019894 A8

- (51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) International Application Number:
PCT/US2016/044545
- (22) International Filing Date:
28 July 2016 (28.07.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/198,492 29 July 2015 (29.07.2015) US
- (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). IMMUTEP S.A.S [FR/FR]; Parc Club Orsay, 2 Rue Jearostand, 91893 Orsay (FR).
- (72) Inventors; and
(71) Applicants (for US only): DRANOFF, Glenn [US/US]; 150 Concord Road, Sudbury, MA 01776 (US). TRIEBEL, Frédéric [FR/FR]; 10 Rue Saint Louis, 78000 Versailles (FR). BRIGNONE, Chrystelle [FR/FR]; 4d Rue Léon Martine, Batiment D, Appartement 02, 92290 Chate-

nay-malabry (FR). BLATTLER, Walter, A. [US/US]; 197 Mason Terrace, Brookline, MA 02446-2768 (US). MATARAZA, Jennifer, Marie [US/US]; 250 Massachusetts Ave., Cambridge, MA 02139 (US). SABATOS-PEYTON, Catherine, Anne [US/US]; 250 Massachusetts Ave., Cambridge, MA 02139 (US). CHANG, Hwai, Wen [US/US]; 1318 Shadow Hills Drive, San Marcos, CA 92069 (US). FREY, Gerhard Johann [DE/US]; 13768 Via Cima Bella, San Diego, CA 92129 (US).

(74) Agent: COLLAZO, Diana M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE,

(54) Title: COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3




FIGURE 15

(57) Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

09 November 2017 (09.11.2017)

(15) Information about Correction:

see Notice of 09 November 2017 (09.11.2017)